BTG ups revenue estimates
BTG, the specialist healthcare company, has upped its full year revenue guidance after a strong showing at its licensing & biotechnology business.
BTG, the specialist healthcare company, has upped its full year revenue guidance after a strong showing at its licensing & biotechnology business.
The firm is raising its revenue estimate for the year ended 31 March 2012 from a forecast of £160m-£165m to £190m-£195m.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company also saw a strong performance from its prostate cancer treatment Zytiga,
Trading at BTC's specialty pharmaceuticals and interventional medicine business divisions had been in line with expectations, it added.
Chief Executive Louise Maki said the company had delivered a strong financial and operating performance across the business.
"Our development programmes are on track and we have made good progress in our interventional medicine business," she added.
-
ISS backs Edinburgh Worldwide’s board as Saba questions SpaceX selloffShareholder advisor ISS has recommended that shareholders vote against Saba’s proposals to replace the board of the Baillie Gifford-managed investment trust
-
13 tax changes in 2026 – which taxes are going up?As 2026 gets underway, we look at what lies ahead in terms of changes to tax rates and allowances this year and how it will affect you.
